1.
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial.
2.
3.
4.
5.
6.
7.
8.
Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock
A longitudinal study highlights shared aspects of the transcriptomic response to cardiogenic and septic shock